Review Says Alzheimer’s Drug Class Ineffective
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Review finds little clinical benefit for a class of Alzheimer’s drugs
- Alzheimer’s experts criticize the analysis for lumping failed drugs with two newly approved treatments
Why it matters: Pharma firms risk losing market share as the review deems their drug class ineffective, while two newly approved treatments may capture more prescriptions, potentially reshaping insurance formularies and research funding.
